Research progress of tumor suppressor gene PTEN and its pseudogene PTENP1 in endometrial carcinoma

doi:10.3877/cma.j.issn.2095-1221.2018.04.012

Abstract

Abstract:

The incidence of endometrial cancer is increasing year by year, which has attracted widespread attention. However, the molecular and genetic mechanismd of endometrial cancer are still unclear. PTEN (phosphatase gene lost on chromosome 10 homologous to tensin) is the gene with the highest mutation rate in endometrial cancer known at present. Detection of its mutation is helpful to early diagnosis, treatment and prognosis evaluation of endometrial cancer and provides a new target for gene therapy of endometrial cancer. In addition, the study found that the transcription of PTENP1 (PTEN's pseudogene) regulates the expression of PTEN, which is believed to be related to the occurrence of some tumors. This article reviews the structure and function of PTEN gene, its mutation in endometrial cancer, its clinical significance and the research status of PTENP1.

Key words: Endometrial carcinoma, PTEN, PTENP1, Gene mutation

Zhiying Ding. Research progress of tumor suppressor gene PTEN and its pseudogene PTENP1 in endometrial carcinoma[J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2018, 08(04): 252-256.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhxbygxbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-1221.2018.04.012

https://zhxbygxbzz.cma-cmc.com.cn/EN/Y2018/V08/I04/252

References 49

1	Li J,Yen C,Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer[J]. Science, 1997, 275(5308):1943-1947.
2	Steck PA,Pershouse MA,Jasser SA, et al. Identification of a candidate tumour suppressor gene,MMAC1,at chromosome I0q23.3 that is mutated in multiple advanced cancers[J]. Nat Genet, 1997, 15(4):356-362.
3	Li DM,Sun H. TEP1, Encoded by a candidate tumor suppressor locus,is a protein tyrosine phosphatase regulated by transforming growth factor beta[J]. Cancer Res, 1997, 57(11):2124-2129.
4	Vazquez F,Sellers WR. The PTEN tumor suppressor protein: an antagonist of phosphoinositide 3-kinase signaling[J]. Biochim Biophys Acta, 2000, 1470(1):M21-M35.
5	Simpson L,Parsons R. PTEN: life as a tumor suppressor[J]. Exp Cell Res, 2001, 264(1):29-41.
6	Lee JO,Yang H,Georgescu MM, et al. Crystal structure of the PTEN tumor suppress:implications for its phosphoinositide phosphatase activity and membrane association[J]. Cell, 1999, 99(3):323-334.
7	Tamura M,Gu J,Takino T, et al. Tumor suppressor PTEN inhibition of cell invasion,migration,and growth:differential involvement of focal adhesion kinase and p130Cas[J]. Cancer Res, 1999, 59(2):442-449.
8	Smith IN,Briggs JM. Structural mutation analysis of PTEN and its Genotype-Phenotype correlations in endometriosis and cancer[J]. Proteins, 2016, 84(11):1625-1643.
9	Hesson LB,Packham D,Pontzer E, et al. A reinvestigation of somatic hypermethylation at the PTEN CpG island in cancer cell lines[J]. Biol Proced Online, 2012, 14(1):5.
10	Poliseno L,Pandolfi PP. PTEN ceRNA networks in human cancer[J]. Methods, 2015, 77-78:41-50.
11	Ioffe YJ,Chiappinelli KB,Mutch DG, et al. Phosphatase and tensin homolog (PTEN) pseudogene expression in endometrial cancer: A conserved regulatory mechanism important in tumorigenesis?[J]. Gynecol Oncol, 2012, 124(2):340-346.
12	Poliseno L,Salmena L,Zhang J, et al. A coding-independent function of gene and pseudogene mRNAs regulates tumour biology[J]. Nature, 2010, 465(7301):1033-1038.
13	Poliseno L,Haimovic A,Christos PJ, et al. Deletion of PTENP1 pseudogene in human melanoma[J]. J Invest Dermatol, 2011, 131(12):2497-2500.
14	Liu J,Xing Y,Xu L, et al. Decreased expression of pseudogene PTENP1 promotes malignant behaviours and is associated with the poor survival of patients with HNSCC[J]. Sci Rep, 2017, 7:41179.
15	Qin X. Yan L,Zhao X, et al. microRNA-21 overexpression contributes to cell proliferation by targeting PTEN in endometrioid endometrial cancer[J]. Oncol Lett, 2012, 4(6):1290-1296.
16	Kovalenko TF,Sorokina AV,Ozolinya LA, et al. Methylation of the pseudogene PTENP1 5'-terminal region in endometrial cancer and hyperplasia[J]. Russ J Bioorg Chem, 2013, 39(4):397-405.
17	Masunaga A,Omatsu M,Kunimura T, et al. Expression of PTEN and its pseudogene PTENP1, and promoter methylation of PTEN in non-tumourous thymus and thymic tumours[J]. J Clin Pathol, 2017, 70(8):690-696.
18	Chen CL,Tseng YW,Wu JC, et al. Suppression of hepatocellular carcinoma by baculovirus-mediated expression of long non-coding RNA PTENP1 and MicroRNA regulation[J]. Biomaterials, 2015, 44(9):71-81.
19	Li RK,Gao J,Guo LH, et al. PTENP1 acts as a ceRNA to regulate PTEN by sponging miR-19b and explores the biological role of PTENP1 in breast cancer[J]. Cancer Gene Ther, 2017, 24(7):309-315.
20	Zhang R,Guo Y,Ma Z, et al. Long non-coding RNA PTENP1 functions as a ceRNA to modulate PTEN level by decoying miR-106b and miR-93 in gastric cancer[J]. Oncotarget, 2017, 8(16):26079-26089.
21	Gao L,Ren W,Zhang L, et al. PTENp1, a natural sponge of miR-21, mediates PTEN expression to inhibit the proliferation of oral squamous cell carcinoma[J]. Mol Carcinog, 2017, 56(4):1322-1334.
22	Johnsson P,Ackley A,Vidarsdottir L, et al. A pseudogene long-noncoding-RNA network regulates PTEN transcription and translation in human cells[J]. Nat Struct Mol Biol, 2013, 20(4):440-446.
23	Kovalenko TF,Sorokina AV,Ozolinia LA, et al. Pseudogene PTENP1 5'-region methylation in endometrial cancer and hyperplasias[J]. Bioorg Khim, 2013, 39(4):445-453.
24	Bokhman JV. Two pathogenetic types of endometrial carcinoma[J]Gynecol Oncol, 1983, 15(1):10-17.
25	Silverberg SG, KurmanRJ, Nogales F, et al, Epithelialtumours and relatedlesions[M] . lyon: iarc press, 2003: 217-232.
26	Pavlidou A,Vlahos NF. Molecular alterations of PI3K/AKT/mTOR pathway: a therapeutic target in endometrial cancer[J]. ScientificWorldJournal, 2014, 2014:709736.
27	Huang HN,Lin MC,Tseng LH, et al. Ovarian and endometrial endometrioid adenocarcinomas have distinct profiles of microsatellite instability, PTEN expression, and ARID1A expression[J]. Histopathology, 2015, 66(4):517-528.
28	Kanamori Y,Kigawa J,Itamochi H, et al. PTEN expression is associated with prognosis for patients with advanced endometrial carcinoma undergoing postoperative chemotherapy[J]. Int J Cancer, 2002, 100(6):686-689.
29	Tashiro H,Blazes MS,Wu R, et al. Mutations in PTEN are frequent in endomctrial carcinoma but rare in other common gynecological malignancies[J]. Cancer Res, 1997, 57(18):3935-3940.
30	Dong P,Konno Y,Watari H, et al. The impact of microRNA-mediated PI3K/AKT signaling on epithelial-mesenchymal transition and cancer stemness in endometrial cancer[J]. J Transl Med, 2014, 12:231.
31	Polivka J Jr,Janku F. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway[J]. Pharmacol Ther, 2014, 142(2):164-175.
32	Slomovitz BM,Coleman RL. The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer[J]. Clin Cancer Res, 2012, 18(21):5856-5864.
33	Bing L,Hong C,Li-Xin S, et al. MicroRNA-543 suppresses endometrial cancer oncogenicity via targeting FAK and TWIST1 expression[J]. Arch Gynecol Obstet, 2014, 290(3):533-541.
34	Tamura M,Gu J,Matsumoto K, et a1. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN[J]. Science, 1998, 280(5369):1614-1617.
35	Zhang LL,Liu J,Lei S, et al. PTEN inhibits the invasion and metastasis of gastric cancer via downregulation of FAK expression[J]. Cell Signal, 2014, 26(5):1011-1020.
36	Dragoj M,Bankovic J,Sereti E, et al. Anti-invasive effects of CXCR4 and FAK inhibitors in non-small cell lung carcinomas with mutually inactivated p53 and PTEN tumor suppressors[J]. Invest New Drugs, 2017, 35(6):718-732.
37	Waite KA,Eng C. Protean PTEN:from and funcdon[J]. Am J Hum Genet, 2002, 70(4):829-844.
38	Diao L,Chen YG. PTEN, a general negative regulator of cyclin D expression[J]. Cell Res, 2007, 17(4):291-292.
39	Yart A,Laffargue M,Mayeux P, et al. A critical role for phosphoinositide 3-kinase upstream of Gab1 and SHP2 in the activation of ras and mitogen-activated protein kinases by epidermal growth factor[J]. J Biol Chem, 2001, 276(12):8856-8864.
40	Weng LP,Smrrh WM,Brown JL, et al. PTEN inhibits insulin-stimulated MEK/MAPK activation and cell growth by blocking IRS-1 phosphorylation and IRS-1/Grb-2/Sos complex formation in a breast cancer model[J]. Hum Mol Genet, 2001, 10(6):605-616.
41	Raouf A E, Ibrahim TR. Expression and significance of PTEN and GLUT-1 in proliferative endometrium, endometrial hyperplasia, and endometrioid adenocarcinoma[J]. Egypt J Patho, 2014, 34(2):117-124.
42	Sal V,Demirkiran F,Erenel H, et al. Expression of PTEN and β-catenin and their relationship with clinicopathological and prognostic factors in endometrioid type endometrial cancer[J]. Int J Gynecol Cancer, 2016, 26(3):512-520.
43	Akiyama-Abe A,Minaguchi T,Nakamura Y, et al. Loss of PTEN expression is an Independent predictor of favourable survival in endometrial carcinomas[J]. Br J Cancer, 2013, 109(6):1703-1710.
44	鲁晓东,卢房利,段钊, 等. TTF-1和PTEN基因在子宫内膜癌早期病变中的表达意义[J]. 昆明医科大学学报, 2017 (8):62-66.
45	Wu Y,Wang YQ,Weng WW, et al. A serum-circulating long noncoding RNA signature can discriminate between patients with clear cell renal cell carcinoma and healthy controls[J]. Oncogenesis, 2016, 5:e192.
46	Dong L,Qi P,Xu MD, et al. Circulating CUDR, LSINCT-5 and PTENP1 long noncoding RNAs in sera distinguish patients with gastric cancer from healthy controls[J]. Int J Cancer, 2015, 137(5):1128-1135.
47	Yu G,Yao W,Gumireddy K, et al. Pseudogene PTENP1 functions as a competing endogenous RNA to suppress Clear-Cell renal cell carcinoma progression[J]. Mol Cancer Ther, 2014, 13(12):3086-3097.
48	Gong T,Zheng S,Huang S, et al. PTENP1 inhibits the growth of esophageal squamous cell carcinoma by regulating SOCS6 expression and correlates with disease prognosis[J]. Mol Carcinog, 2017, 56(12): 2610-2619.
49	Mitamura T,Dong P,Ihira K, et al. Molecular-targeted therapies and precision medicine for endometrial cancer[J]. Jpn J Clin Oncol, 2018. doi: 10.1093/jjco/hyy159. [Epub ahead of print]

[1]	Tiantian Chen, Xiaodong Wang, Haiyan Yu. Pregnancy outcome of twin pregnancy with Gitelman syndrome: a case report and literature review [J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2023, 19(05): 559-568.
[2]	Lulan Kan, Maoqiang Tian, Yimi Tang. Children with mild Gitelman syndrome presenting with recurrent abdominal pain: a case report and literature review [J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2023, 19(04): 473-479.
[3]	Jialin Mu, Xuefei Leng, Fei Tian, Lina Wang, Zhihong Chen. Sotos syndeome with a novel mutation in NSD1 gene: a case report and domestic literature review [J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2022, 18(06): 692-702.
[4]	Youren Dai, Yue Zhang, Yang Li, Cong Wang, Ting Chen, Wenjun Cheng, Chengyan Luo. Clinicopathological features and treatment of undifferentiated/dedifferentiated endometrial carcinoma [J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2022, 18(06): 660-668.
[5]	Xufeng Luo, Jianxiang Liao, Zhiqiang Luo, Jing Duan, Yongli Li, Jianfang Xu, Li Chen. Na⁺ channel blockers in treatment of early-onset epileptic encephalopathy caused by SCN2A gene variation: a case report and literature review [J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2022, 18(05): 585-590.
[6]	Mu Du, Xiaobo Chen, Fuying Song, Ziqin Liu, Kun Qian. Clinical characteristics and genetic analysis of vitamin D-dependent rickets ⅠA caused by CYP27B1 gene mutation [J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2022, 18(02): 175-184.
[7]	Yutao Yuan, Jinlin Xing, Kefei Xie, Kai Yin. Correlation between CT findings and BRAF^V600E gene mutation and central lymph node metastasis in papillary thyroid carcinoma [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(06): 611-614.
[8]	Lifang Jia, Yuping Zhang, Wenying Bai, Peiyi Zhou, Jiazheng Wang. Protective effect of long noncoding ribonucleic acid LINC00261 on HK-2 cells in high glucose environment via miR-148b-3p/PTEN pathway [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2022, 11(01): 22-28.
[9]	Haoli Fu, Cheng Zhang, Shuting Liang, Zequn Miao, Qingyu Meng, Lynzhen Huang, Lili Guo, Qianru Ouyang, Xin Xu, Yu Cao, Jingyi Zhang, Lejin Wang. Identificationon of a novel nonsense mutation of FRMD7 in a family with congenital nystagmus [J]. Chinese Journal of Ophthalmologic Medicine(Electronic Edition), 2022, 12(03): 152-157.
[10]	Cuiping Yang, Xiaojin Yang, Xu Quan, Ling Xie, Yunlin Wu, Ping Chen. Effects of hepatocyte nuclear factor-1α mutation and adenomatous polyposis coli mutation on familial adenomatous polyposis cell proliferation [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2022, 12(04): 228-231.
[11]	Jing He, Jie Shi, Jiuluan Lin, Zhaohui Sun, Haixiang Wang, Bingqing Zhang, Yiou Liu, Xiancheng Song, Qian Feng, Jianjun Bai, Wenjing Zhou. Surgical treatment of tuberous sclerosis with refractory epilepsy in children [J]. Chinese Journal of Clinicians(Electronic Edition), 2021, 15(08): 597-600.
[12]	Qian Wang, Yongping Wang, Xinpei Li, Chengyan Yang, Hui Xu, Fengjuan Sun, Yaping Liu. Diagnostic characteristics of hypokalemia with gene mutations [J]. Chinese Journal of Diagnostics(Electronic Edition), 2023, 11(02): 115-119.
[13]	Wenxia Shi, Yongxin Guo, Junjie Shen, Wenming Chen, Wenwen Guo, Tongfeng Zhao, Dandan Zhao, Jian Chen, Zhongliang Sun, Daoping Sun. The impact of RUNX1 mutations on clinical characteristics, therapeutic efficacy, and prognosis in adults with acute myeloid leukemia [J]. Chinese Journal of Diagnostics(Electronic Edition), 2022, 10(03): 163-170.
[14]	Hui Huang, Weiyun Wang, Chen Cheng, Ya Liu, Xinlin Chen. Prenatal diagnostic characteristics and literature review of Meckel-Gruber syndrome [J]. Chinese Journal of Diagnostics(Electronic Edition), 2022, 10(02): 77-82.
[15]	Zhenyuan Zhai, Jinxia Huang, Xiaoyan Liu. Laparoscopic extrafascial hysterectomy, bilateral adnexectomy plus laparoscopic indocyanine green fluorescence guided sentinel lymphadenectomy for middle and old aged patients with endometrial carcinoma [J]. Chinese Journal of Geriatrics Research(Electronic Edition), 2022, 09(04): 26-29.

Please choose a citation manager

Content to export